Major financial milestone via Series D1 funding On January 23, 2026, Corxel Pharmaceuticals announced the closure of a $287 million Series D1 financing round. The funding attracted new institutional investors, including SR One, TCGX, and RA Capital Management, alongside continued support from existing backers like RTW Investments. This substantial raise highlights the persistent investor enthusiasm for the obesity and weight-loss drug sector.
Clinical progress of lead candidate CX11 The primary focus of this investment is the development of CX11, an oral glucagon-like peptide-1 receptor agonist (GLP-1RA). The drug is currently moving through high-stakes clinical trials:
-
United States: Currently in Phase II clinical evaluation.
-
China: Progressing through Phase III trials (overseen by Vincentage).
Earlier clinical data released in June 2025 indicated that patients on a fast-titration schedule of the highest dose achieved a 9.7% reduction in body weight over a 16-week period.